questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Proline-directed protein kinases
Kinases cyclines-dépendantes
Kinases CDC2-CDC28
Kinases CDC2-CDC28 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Diagnostic médical
Tests de laboratoire
Kinases
Marqueurs biologiques
Kinases
Symptômes
5
Symptômes
Cycle cellulaire
Division cellulaire
Kinases
Anomalies morphologiques
Kinases
Prévention
5
Prévention
Facteurs de risque
Dépistage
Antécédents familiaux
Exercice physique
Prévention
Traitements
5
Traitements ciblés
Kinases
Inhibiteurs de kinases
Administration de médicaments
Effets secondaires
Kinases
Médecine personnalisée
Kinases
Complications
5
Système immunitaire
Kinases
Résistance aux traitements
Kinases
Réversibilité
Complications
Gestion des complications
Suivi médical
Facteurs de risque
5
Facteurs de risque
Génétique
Tabagisme
Facteurs de risque
Alimentation
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Kinases CDC2-CDC28 : Questions médicales les plus fréquentes",
"headline": "Kinases CDC2-CDC28 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Kinases CDC2-CDC28 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-18",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Kinases CDC2-CDC28"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Kinases cyclines-dépendantes",
"url": "https://questionsmedicales.fr/mesh/D018844",
"about": {
"@type": "MedicalCondition",
"name": "Kinases cyclines-dépendantes",
"code": {
"@type": "MedicalCode",
"code": "D018844",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-kinase CDC28 de S. cerevisiae",
"alternateName": "CDC28 Protein Kinase, S cerevisiae",
"url": "https://questionsmedicales.fr/mesh/D017489",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-kinase CDC28 de S. cerevisiae",
"code": {
"@type": "MedicalCode",
"code": "D017489",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500.500.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Kinase-5 cycline-dépendante",
"alternateName": "Cyclin-Dependent Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D051360",
"about": {
"@type": "MedicalCondition",
"name": "Kinase-5 cycline-dépendante",
"code": {
"@type": "MedicalCode",
"code": "D051360",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.646.500.500.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Kinases CDC2-CDC28",
"alternateName": "CDC2-CDC28 Kinases",
"code": {
"@type": "MedicalCode",
"code": "D042846",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rebecca B Riggins",
"url": "https://questionsmedicales.fr/author/Rebecca%20B%20Riggins",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA."
}
},
{
"@type": "Person",
"name": "Zhengqing Yang",
"url": "https://questionsmedicales.fr/author/Zhengqing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Hui Cheng",
"url": "https://questionsmedicales.fr/author/Hui%20Cheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Yazhou Zhang",
"url": "https://questionsmedicales.fr/author/Yazhou%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
},
{
"@type": "Person",
"name": "Yan Zhou",
"url": "https://questionsmedicales.fr/author/Yan%20Zhou",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Proline-directed protein kinases",
"item": "https://questionsmedicales.fr/mesh/D038461"
},
{
"@type": "ListItem",
"position": 7,
"name": "Kinases cyclines-dépendantes",
"item": "https://questionsmedicales.fr/mesh/D018844"
},
{
"@type": "ListItem",
"position": 8,
"name": "Kinases CDC2-CDC28",
"item": "https://questionsmedicales.fr/mesh/D042846"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Kinases CDC2-CDC28 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Kinases CDC2-CDC28",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Kinases CDC2-CDC28",
"description": "Comment diagnostiquer une dysfonction des kinases CDC2-CDC28 ?\nQuels tests sont utilisés pour évaluer l'activité des kinases CDC2-CDC28 ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs biologiques sont associés aux kinases CDC2-CDC28 ?\nLes tests génétiques sont-ils nécessaires pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Kinases CDC2-CDC28",
"description": "Quels symptômes indiquent une anomalie des kinases CDC2-CDC28 ?\nLes troubles de la division cellulaire sont-ils liés aux kinases CDC2-CDC28 ?\nPeut-on observer des anomalies morphologiques cellulaires ?\nLes cancers sont-ils liés aux dysfonctionnements des kinases CDC2-CDC28 ?\nY a-t-il des signes cliniques spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Kinases CDC2-CDC28",
"description": "Peut-on prévenir les dysfonctionnements des kinases CDC2-CDC28 ?\nY a-t-il des mesures préventives spécifiques ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nL'exercice physique peut-il aider à prévenir des anomalies ?\nLes vaccinations ont-elles un impact sur les kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Kinases CDC2-CDC28",
"description": "Quels traitements ciblent les kinases CDC2-CDC28 ?\nLes thérapies géniques sont-elles une option ?\nComment les inhibiteurs de kinases sont-ils administrés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Kinases CDC2-CDC28",
"description": "Quelles complications peuvent survenir avec des anomalies des kinases ?\nLes anomalies des kinases peuvent-elles affecter d'autres systèmes ?\nY a-t-il des risques de résistance aux traitements ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées aux kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Kinases CDC2-CDC28",
"description": "Quels sont les principaux facteurs de risque pour les anomalies des kinases ?\nL'âge est-il un facteur de risque ?\nLe tabagisme influence-t-il les kinases ?\nY a-t-il un lien entre l'alimentation et les kinases ?\nLe stress peut-il affecter les kinases ?",
"url": "https://questionsmedicales.fr/mesh/D042846?mesh_terms=Proprotein+Convertase+9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des kinases CDC2-CDC28 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses de protéines spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des kinases CDC2-CDC28 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des dosages enzymatiques sont utilisés pour mesurer leur activité."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent révéler des anomalies dans l'expression des kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux kinases CDC2-CDC28 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme cyclines et phosphorylations spécifiques sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils nécessaires pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une anomalie des kinases CDC2-CDC28 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la croissance cellulaire anormale ou des troubles du cycle cellulaire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles de la division cellulaire sont-ils liés aux kinases CDC2-CDC28 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans ces kinases peuvent entraîner des troubles de la division cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies morphologiques cellulaires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies morphologiques peuvent être observées dans les cellules affectées."
}
},
{
"@type": "Question",
"name": "Les cancers sont-ils liés aux dysfonctionnements des kinases CDC2-CDC28 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements peuvent contribuer à la carcinogenèse et à la progression tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hyperplasie ou des anomalies dans le cycle cellulaire doivent être surveillés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases CDC2-CDC28 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la réduction des facteurs de risque environnementaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers et une surveillance des antécédents familiaux sont recommandés."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut contribuer à la santé cellulaire et à la prévention."
}
},
{
"@type": "Question",
"name": "L'exercice physique peut-il aider à prévenir des anomalies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier favorise la santé cellulaire et peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un impact sur les kinases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent réduire le risque de cancers associés aux dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases CDC2-CDC28 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des kinases sont utilisés pour traiter les dysfonctionnements associés."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut corriger des mutations affectant les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs de kinases sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou intraveineuse, selon le médicament."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme la toxicité cellulaire peuvent survenir avec certains traitements."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, des troubles métaboliques et des anomalies cellulaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases peuvent-elles affecter d'autres systèmes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir des répercussions sur le système immunitaire et d'autres systèmes organiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les kinases peuvent entraîner une résistance aux traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux kinases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies des kinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques, l'exposition à des agents cancérigènes et des habitudes de vie."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies des kinases augmente avec l'âge en raison de l'accumulation de mutations."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les kinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour des anomalies dans les kinases CDC2-CDC28."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'alimentation et les kinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses et en sucres peut augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter les kinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut influencer l'expression et l'activité des kinases CDC2-CDC28."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 14/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland).
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland).
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland).
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Shanghai Yangsi Hospital, Shanghai, China (mainland).
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology and Immunology, Washington University in St Louis, School of Medicine, St Louis, MO, USA.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology and Immunology, Washington University in St Louis, School of Medicine, St Louis, MO, USA.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology and Immunology, Washington University in St Louis, School of Medicine, St Louis, MO, USA. kmurphy@wustl.edu.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 26-28, Nijmegen, 6525GA, the Netherlands.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 26-28, Nijmegen, 6525GA, the Netherlands.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 26-28, Nijmegen, 6525GA, the Netherlands.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein Zuid 26-28, Nijmegen, 6525GA, the Netherlands.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Plant Protection, Shandong Agricultural University, Tai'an 271018, China.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, University of California, San Diego, California, USA.
Department of Chemistry and Biochemistry, University of California, San Diego, California, USA.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Publications dans "Kinases CDC2-CDC28" :
2 publications dans cette catégorie
Affiliations :
Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary. Electronic address: remenyi.attila@ttk.mta.hu.
Publications dans "Kinases CDC2-CDC28" :
1 publication dans cette catégorie
Affiliations :
School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand.
Publications dans "Kinases CDC2-CDC28" :
1 publication dans cette catégorie
Affiliations :
School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand. Electronic address: daniel.foley@canterbury.ac.nz.
Publications dans "Kinases CDC2-CDC28" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan Amman 11942 Jordan mutasem@ju.edu.jo.
Publications dans "Kinases CDC2-CDC28" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Sciences Private University Amman Jordan.
Publications dans "Kinases CDC2-CDC28" :
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...